The relationship between the single-nucleotide polymorphisms rs1978124 and rs2074192 of the ACE2 gene in individuals with type 2 diabetes infected with COVID-19

Ghaleb Hussein Obaid Al-Saeedi, Wisam Salih Abood

Abstract


Background: Understanding of the complexity and importance of ACE2 gene from the perspective of two genotypes (rs1978124 and rs2074192) and their role in pancreatic deterioration is gaining prominence these days. The ACE2 role is considered important in characterizing different factors when diabetic patients interact with viruses like SARS-CoV-2.

Methods: Blood samples were collected from 120 participants and divided into three groups for a cross-sectional and observational study. The first group was admitted to the COVID-19 isolation wards, and 40 of them were infected with the SARS-CoV-2 virus. Most of them had diabetes, while the other groups included 40 patients with diabetes only, and 40 control samples. The test was performed using ARMS-PCR technology.

Result: The results showed differences in ACE2 genotype and allele frequencies among the study groups, with a statistically significant association observed only for the T allele of rs2074192 in COVID-19 patients with diabetes compared with healthy controls. When investigating rs2074192 genotype in COVID-19 patients with diabetes compared with diabetes-only patients, C/T (OR = 1.458) and TT (OR = 1.167) showed OR values above 1, but these findings were not statistically significant.

Conclusion: After the virus binds to the ACE2 receptor of pancreatic cells, it results in the destruction of beta cells and an increase in the rate of pancreatic fibrosis due to a decrease in blood flow in the blood vessels, and a decrease in insulin secretion, which leads to diabetes.

Keywords:

Coronavirus-19, SNP, ACE2, Pancreas, SARS-CoV-2, Diabetes

Full Text:

PDF

References


Wu F, Zhao S, Yu B, Chen YM, Wang W, et al. A new coronavirus associated with human respiratory disease in China. Nature, (2020); 579(7798): 265-269.

Hasan SS, Capstick T, Ahmed R, Kow CS, Mazhar F, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert review of respiratory medicine, (2020); 14(11): 1149-1163.

Zhou L, Niu Z, Jiang X, Zhang Z, Zheng Y, et al., Systemic analysis of tissue cells potentially vulnerable to SARS-CoV-2 infection by the protein-proofed single-cell RNA profiling of ACE2, TMPRSS2 and Furin proteases, [https://www.biorxiv.org/content/biorxiv/early/2020/07/21/2020.04.06.028522.full.pdf](https://www.biorxiv.org/content/biorxiv/early/2020/07/21/2020.04.06.028522.full.pdf), Accessed on: 18.02.2025.

Xu H, Zhong L, Deng J, Peng J, Dan H, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science, (2020); 12(1): 1-5.

Astuti I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, (2020); 14(4): 407–412.

Hatmal MM, Alshaer W, Al-Hatamleh MA, Hatmal M, Smadi O, et al. Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2. Cells, (2020); 9(12): 2638.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, (2020); 181(2): 271-280.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐Diabetes/metabolism research and reviews, (2020); 36(7): e3319.

Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection, (2020); 53(3): 425-435.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, (2020); 367(6485): 1444-1448.

Mudhafar M, Abdulrasool MM, Nasser L. Investigation on the antibacterial activity and phytochemical screening of the fruit seed extracts of agro waste. Journal of US-China Medical Science, (2019); 16(2019): 223-231.

Evans JP, Liu SL. Role of host factors in SARS-CoV-2 entry. Journal of Biological Chemistry, (2021); 297(1): 100847.

Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annual review of microbiology, (2019); 73(1): 529-557.

Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, Transmission, and Pathogenesis of Sars-Cov-2. BMJ, (2020); 371(2020): m3862.

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. National Science Review, (2020); 7(6): 998-1002.

Hackbart M, Deng X, Baker SC. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proceedings of the National Academy of Sciences, (2020); 117(14): 8094–8103.

Sabater Molina M, Nicolás Rocamora E, Bendicho AI, Vázquez EG, Zorio E, et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS one, (2022); 17(2): e0263140.

Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. European heart journal, (2020); 41(19): 1810-1817.

Patel SK, Wai B, Ord M, MacIsaac RJ, Grant S, et al. Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. American Journal of Hypertension, (2022); 25(2): 216-222.

Liu C, Li Y, Guan T, Lai Y, Shen Y, et al. ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovascular diabetology, (2018); 17(2018): 1–11.

Duffy S. Why are RNA virus mutation rates so damn high?. PLoS biology, (2018); 16(8): e3000003.

Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature reviews microbiology, (2021); 19(7): 409–424.

Viveiros A, Rasmuson J, Vu J, Mulvagh SL, Yip CY, et al. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. American Journal of Physiology-Heart and Circulatory Physiology, (2021); 320(1): H296–H304.

Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, et al. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?. International Journal of Molecular Sciences, (2020); 21(10): 3474.

Liu F, Long X, Zhang B, Zhang W, Chen X, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clinical Gastroenterology and Hepatology, (2020); 18(9): 2128-2130.

Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell, (2020); 27(1): 125-136.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet, (2020); 395(10234): 1417-1418.

Ghosal S, Sinha B, Majumder M, Misra A. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: a simulation model using multivariate regression analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, (2020); 14(4): 319-323.

World Health Organization, Clinical management of COVID-19: Living guideline, [https://pesquisa.bvsalud.org/portal/resource/essiqueira/biblio-1393163](https://pesquisa.bvsalud.org/portal/resource/essiqueira/biblio-1393163), Accessed on: 18.02.2025.

Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nature Reviews Immunology, (2020); 20(7): 397–398.

Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 2009. John Wiley & Sons.

Medina-Enríquez MM, Lopez-León S, Carlos-Escalante JA, Aponte-Torres Z, Cuapio A, et al. ACE2: the molecular doorway to SARS-CoV-2. Cell & Bioscience, (2020); 10(1): 148.

Ma Y, Li Q, Chen J, Liu S, Liu S, et al. Angiotensin-converting enzyme 2 SNPs as common genetic loci and optimal early identification genetic markers for COVID-19. Pathogens, (2022); 11(8): 947.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet Respiratory Medicine, (2020); 8(4): e21.

Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. Journal of Endocrinological Investigation, (2020); 43(7): 1027-1031.

AlGhatrif M, Tanaka T, Moore AZ, Bandinelli S, Lakatta EG, et al. Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study. Geroscience, (2021); 43(2021): 619-627.

Faridzadeh A, Mahmoudi M, Ghaffarpour S, Zamani MS, Hoseinzadeh A, et al. The role of ACE1 I/D and ACE2 polymorphism in the outcome of Iranian COVID-19 patients: A case-control study. Frontiers in Genetics, (2022); 13(2022): 955965.

Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes research and clinical practice, (2020); 166(2020): 108347.

Filardi T, Morano S. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?. Journal of endocrinological investigation, (2020); 43(2020): 1053-1060.

Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL, et al. Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Human genomics, (2020); 14(1): 1-6.

Sharma P, Behl T, Sharma N, Singh S, Grewal AS, et al. COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. Biomedicine & Pharmacotherapy, (2022); 151(2022): 113089.

Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?. Diabetes, Obesity and Metabolism, (2016); 18(7): 641-647.




DOI: https://doi.org/10.62940/als.v13i1.2226

Refbacks

  • There are currently no refbacks.